NCT04755023View on ClinicalTrials.gov

Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 21, 2005

Primary Completion Date

March 15, 2009

Study Completion Date

December 15, 2010

Conditions
Oligodendroglioma; Oligoastrocytoma
Interventions
DRUG

Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide

Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.

Trial Locations (1)

13005

Assistance Publique - Hôpitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT04755023 - Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis | Biotech Hunter | Biotech Hunter